Cheng Xu, Li Dapeng, Xu Jiaxi, Wei Bing, Fang Qin, Yang Longshun, Xue Yanbing, Wang Xin, Tang Rupei
Engineering Research Center for Biomedical Materials, Anhui Key Laboratory of Modern Biomanufacturing, School of Life Sciences, Anhui University, Hefei 230601, China.
School of Life Sciences, Anqing Normal University, Anqing 246133, China.
Acta Pharm Sin B. 2021 Nov;11(11):3595-3607. doi: 10.1016/j.apsb.2021.03.041. Epub 2021 Apr 2.
Traditional chemotherapy exhibits a certain therapeutic effect toward malignant cancer, but easily induce tumor multidrug resistance (MDR), thereby resulting in the progress of tumor recurrence or metastasis. In this work, we deigned ternary hybrid nanodrugs (PEI/DOX@CXB-NPs) to simultaneously combat against tumor MDR and metastasis. results demonstrate this hybrid nanodrugs could efficiently increase cellular uptake at pH 6.8 by the charge reversal, break lysosomal sequestration by the proton sponge effect and trigger drugs release by intracellular GSH, eventually leading to higher drugs accumulation and cell-killing in drug-sensitive/resistant cells. evaluation revealed that this nanodrugs could significantly inhibit MDR tumor growth and simultaneously prevent A549 tumor liver/lung metastasis owing to the specifically drugs accumulation. Mechanism studies further verified that hybrid nanodrugs were capable of down-regulating the expression of MDR or metastasis-associated proteins, lead to the enhanced anti-MDR and anti-metastasis effect. As a result, the multiple combination strategy provided an option for effective cancer treatment, which could be potentially extended to other therapeutic agents or further use in clinical test.
传统化疗对恶性肿瘤具有一定的治疗效果,但容易诱导肿瘤多药耐药(MDR),从而导致肿瘤复发或转移的进展。在这项工作中,我们设计了三元杂化纳米药物(PEI/DOX@CXB-NPs)来同时对抗肿瘤MDR和转移。结果表明,这种杂化纳米药物可以通过电荷反转在pH 6.8时有效增加细胞摄取,通过质子海绵效应打破溶酶体隔离,并通过细胞内谷胱甘肽触发药物释放,最终导致在药物敏感/耐药细胞中更高的药物积累和细胞杀伤。评估显示,由于特异性的药物积累,这种纳米药物可以显著抑制MDR肿瘤生长并同时预防A549肿瘤的肝/肺转移。机制研究进一步证实,杂化纳米药物能够下调MDR或转移相关蛋白的表达,从而增强抗MDR和抗转移效果。因此,这种多重组合策略为有效的癌症治疗提供了一种选择,有望扩展到其他治疗药物或进一步用于临床试验。